(Q43687360)

25 November 2017

A triple therapy regimen after failed Helicobacter pylori treatments (English)

1 reference

25 November 2017

1 reference

Zullo A

1

1 reference

25 November 2017

Hassan C

2

1 reference

25 November 2017

Campo SM

3

1 reference

25 November 2017

Lorenzetti R

4

1 reference

25 November 2017

Febbraro I

5

1 reference

25 November 2017

De Matthaeis M

6

1 reference

25 November 2017

Porto D

7

1 reference

25 November 2017

Morini S

8

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

Alimentary Pharmacology & Therapeutics

25 November 2017

1 reference

25 November 2017

15

1 reference

25 November 2017

8

1 reference

25 November 2017

1193-1197

1 reference

Duodenal stenosis and Helicobacter pylori.

25 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Efficacy of a multistep strategy for Helicobacter pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Helicobacter pylori infection in ulcer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Long-term sequelae of Helicobacter pylori gastritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Myofibroblast proliferation, fibrosis, and defective pancreatic repair induced by cyclosporin in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Gastric Pathology in Cholecystectomy Patients: Role of Helicobacter pylori and Bile Reflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

Ascorbic acid and intestinal metaplasia in the stomach: a prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01028.X

10.1046/J.1365-2036.2001.01028.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference